Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain
about
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesHistone lysine methyltransferases as anti-cancer targets for drug discoveryMolecular architecture of polycomb repressive complexesHistone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoniSelective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemiaStructural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.The Human Mixed Lineage Leukemia 5 (MLL5), a Sequentially and Structurally Divergent SET Domain-Containing Protein with No Intrinsic Catalytic Activity.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Structural analysis of an active fungal PRC2.Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomasSomatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaStructural insights into conformational stability of both wild-type and mutant EZH2 receptorEZH2: an emerging role in melanoma biology and strategies for targeted therapy.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.Polycomb repressive complex 2 in an autoinhibited state.Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.Mrg15 stimulates Ash1 H3K36 methyltransferase activity and facilitates Ash1 Trithorax group protein function in Drosophila.Structure, mechanism, and regulation of polycomb repressive complex 2.Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.STRUCTURAL BIOLOGY. Chromatin complex, crystal clear.Combined HAT/EZH2 modulation leads to cancer-selective cell death.An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.Roles of H3K36-specific histone methyltransferases in transcription: antagonizing silencing and safeguarding transcription fidelity
P2860
Q27319398-6770DEDB-0784-482B-9E36-5E70BBB5B134Q27702306-0F6D2183-D5E0-46A5-9884-AA8363B6FC73Q27853201-52ACCBC9-943F-425F-91A4-34220D127FACQ28076288-744A7836-4680-411F-A94E-FFA0257F3A69Q33364784-25D062C6-C042-4A17-8F89-DE4BDBDC07B3Q33602816-D3554FD0-E61E-4725-9356-53B235AC0278Q34876825-2501DFDF-3BF2-4B0F-A59E-94D22A1F333EQ35228394-77DC5FAE-CD3D-4AC8-A3B4-F7EAFE06CE54Q36182103-256AFA62-C55E-4A99-82B5-CFA3BBCD7F21Q36445523-B1B983C6-6139-494D-ACF2-DCD6E35471FAQ36956610-9AB61AEF-252F-4308-8916-C75778BFE2F6Q37189669-269341B0-DCC8-4999-96D7-B5F961917DFAQ37217469-94937E9F-9176-4C46-B5D1-BEE57E6DD793Q37218158-1A0A4CD7-BB77-49E0-8458-65CF47F47612Q37319519-38F22590-96D5-4ADA-8427-79525F217488Q38218836-28961A94-40DB-4918-8A16-43EA8E87A34AQ38261107-6552CEF9-5C31-4C6D-88C1-5DABC5F560E4Q38273535-822D9CA0-F06D-49EC-AA0B-82693543EF70Q38728946-D231D574-1896-40D6-B3DB-17251E7A1976Q38906194-569344DD-7B56-4B5B-9297-F529ED516735Q40968408-8B320AD6-C5ED-4EDB-996F-FD7859C35C1AQ45754918-9AAF21AA-C759-4338-9964-6ECD93DC3710Q47948466-A48E7AB7-2824-4B3B-BD40-8226DBA08A37Q52639446-C4C31496-09FC-4A79-B098-69CC9DF0FFCDQ53481285-48D42827-8508-4ECB-9035-3A0227E70879Q55093017-B8BDC2EE-F251-4B1C-A7D3-312E943A39DFQ55346934-8F9FC182-1047-4F86-96EA-24F48204E7E5Q57498154-12BA174C-802B-48EE-B21F-2AFF3E8E0AFD
P2860
Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@ast
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@en
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@nl
type
label
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@ast
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@en
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@nl
prefLabel
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@ast
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@en
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@nl
P2093
P2860
P3181
P1433
P1476
Structural Context of Disease- ...... nalysis of the EZH2-SET Domain
@en
P2093
Aiping Zhang
Bradley Condon
Feiyu Zhang
Iain MacEwan
Jeffrey B Bonanno
John Gately Luz
Logan Rodgers
Marijane Russell
Sheela Ashok
Stephen Antonysamy
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0084147
P407
P577
2013-01-01T00:00:00Z